This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 177 trials Clear all
Filter by:

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma, Amyloidosis
    Multiple Myeloma, Amyloidosis
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or pomalidomide. Some patients may experience an allergic reaction to these drugs which would mean stopping the treatment. The purpose of this research study is to see how safe and useful desensitization is in allowing patients to receive further treatment with lenalidomide or pomalidomide.

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  • Status Recruiting
    Recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Immediate Release (IR) Formulation, Drug: Gastro-Retentive (GR) Formulation, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 100 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Immediate Release (IR) Formulation, Drug: Gastro-Retentive (GR) Formulation, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, West Hollywood, California, United States

Brief Summary

A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.

Combination Study for High Risk Multiple Myeloma Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Carfilzomib, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Carfilzomib, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

Brief Summary

Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge. Elotuzumab (ELO) is a humanized monoclonal antibody that recognizes CS1/CD139, a molecule highly expressed in MM cells. The ELO (10 mg/kg), lenalidomide (LEN) and dexamethasone (DEX) combination achieves high overall response rates (ORR) and long progression-free survival (PFS) for patients with relapsed/refractory disease (RR) MM and those with impaired renal function. However, its efficacy for MM patients with high risk characteristics is still unknown. Pomalidomide (POM) is a recently approved immunomodulatory agent (IMiD) that produces response rates for high-risk RRMM patients when used in combination with DEX and other agents, including the proteasome inhibitor (PI) bortezomib (BTZ). POM has also demonstrated activity for LEN refractory patients. Carfilzomib (CFZ) is a potent second generation PI that has shown to be efficacious for IMiD and BTZ refractory patients as well as high risk patients carrying cytogenetic abnormalities. In this study, we propose to evaluate efficacy and safety of ELO in combination with POM, DEX and CFZ for high-risk RRMM patients.

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

Brief Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: ACY-241, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ACY-241, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Arizona, Tucson, Arizona, United States

Brief Summary

This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma (MM).

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Winship Cancer Institute, Atlanta, Georgia, United States

Brief Summary

The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Genetic Condition, Multiple Myeloma, Relapsed and Refractory Mult...
    Genetic Condition, Multiple Myeloma, Relapsed and Refractory Mult...
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Ixazomib/Pomalidomide/Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Ixazomib/Pomalidomide/Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  • Status Recruiting
    Recruiting
  • Condition Relapsed/Refractory Multiple Myeloma
    Relapsed/Refractory Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: AMG 701, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: AMG 701, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic - Arizona, Phoenix, Arizona, United States

Brief Summary

The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Relapsed/Refractory, Multiple Myeloma
    Relapsed/Refractory, Multiple Myeloma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: TAK-079, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: TAK-079, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope - Duarte, Duarte, California, United States

Brief Summary

The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone (PomDex) in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-079 monotherapy in Phase 2a in participants with r/r MM.